Compare NOMA & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMA | TELA |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 31.4M |
| IPO Year | 2025 | 2019 |
| Metric | NOMA | TELA |
|---|---|---|
| Price | $1.57 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 16.9K | ★ 163.5K |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | $6,376.00 | ★ $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $1.31 | $0.50 |
| 52 Week High | $10.00 | $1.52 |
| Indicator | NOMA | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 39.64 |
| Support Level | $1.40 | $0.93 |
| Resistance Level | $2.09 | $0.97 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 6.75 | 2.72 |
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.